Intellia Therapeutics (Nasdaq: NTLA) granted equity awards to six new employees under its 2024 Inducement Plan. On June 1, 2026, they received time-based RSUs for an aggregate 47,150 common shares, vesting in three equal annual installments over three years.
The awards were approved by the compensation committee as a material inducement to employment and granted outside stockholder-approved plans, in line with Nasdaq Listing Rule 5635(c)(4). Vesting requires continued service with Intellia.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – NTLA
-0.37%
13 alerts
-0.37%Session close to close
$1.88BMarket Cap
0.3xRel. Volume
In the Jun 8 session, NTLA declined 0.37%, reflecting a mild negative market reaction.
Our momentum scanner triggered 13 alerts that day, indicating notable trading interest and price volatility.
This announcement details inducement equity awards for six new employees, totaling 47,150 time-based...
Analysis
This announcement details inducement equity awards for six new employees, totaling 47,150 time-based RSUs vesting over 3 years under Nasdaq Listing Rule 5635(c)(4). It follows recent capital-raising and pivotal Phase 3 updates that strengthened Intellia’s balance sheet and clinical profile. Investors monitoring dilution and governance may track the scale and frequency of such awards alongside future clinical milestones, financing actions, and regulatory filings to contextualize their impact.
Key Figures
Inducement RSUs granted:47,150 sharesNew employees:6 individualsVesting period:3 years
3 metrics
Inducement RSUs granted47,150 sharesTime-based RSUs granted June 1, 2026 under 2024 Inducement Plan
New employees6 individualsEmployees receiving inducement grants under Nasdaq Rule 5635(c)(4)
Vesting period3 yearsOne-third of RSUs vest annually over three years
Underwritten public offering of common stock at $10.75 per share with added dilution.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Recent NTLA news events have mostly seen price moves directionally aligned with the perceived tone of each announcement.
Recent Company History
Over the last few months, Intellia has balanced clinical, financing, and corporate updates. Positive Phase 3 HAELO data for lonvo-z and an underwritten offering supported funding into 2028, while a subsequent 10-Q and 8-K detailed the trial’s 87% HAE attack reduction and cash of $517.2M. Investor conferences and prior inducement grants also featured. Against this backdrop, the latest Nasdaq Rule 5635(c)(4) inducement RSUs continue a pattern of using targeted equity awards alongside capital-raising and pivotal clinical milestones.
"focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies"
CRISPR gene editing is a lab technique that lets scientists cut, remove or change specific bits of an organism’s DNA using a guided molecular "scissors". Investors care because it underpins potential new medicines, agricultural products and diagnostics that can create large markets or regulatory risks; successes or failures in trials, patents or approvals can quickly change a company’s value like a technology breakthrough or setback.
restricted stock unitsfinancial
"time-based restricted stock units (“RSUs”) for an aggregate of 47,150 shares"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
rsusfinancial
"time-based restricted stock units (“RSUs”) for an aggregate of 47,150 shares"
RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.
nasdaq listing rule 5635(c)(4)regulatory
"approved by Intellia’s compensation committee as a material inducement ... in accordance with Nasdaq Listing Rule 5635(c)(4)"
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
equity incentive plansfinancial
"awards were granted outside of Intellia’s stockholder-approved equity incentive plans"
Equity incentive plans are company programs that pay employees, executives, or directors with company stock, stock options, or share units instead of or in addition to cash, aiming to align their interests with shareholders—like giving team members a stake in the house they help build. For investors this matters because such plans can motivate better company performance but also dilute existing ownership and increase reported compensation costs, so they affect future earnings, voting power, and share value.
inducement grantsfinancial
"it awarded inducement grants to six new employees under Intellia’s 2024 Inducement Plan"
Inducement grants are special awards of shares or stock options given to new employees to encourage them to join a company or accept a new role. They act like a welcome bonus, providing an extra incentive to attract talent. For investors, these grants can impact a company's costs and share structure, influencing the value of their investments.
CAMBRIDGE, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that on June 1, 2026, it awarded inducement grants to six new employees under Intellia’s 2024 Inducement Plan, as amended, as a material inducement to employment.
The inducement grants consisted of time-based restricted stock units (“RSUs”) for an aggregate of 47,150 shares of Intellia’s common stock, with one-third of such RSUs vesting annually over three years. All equity vesting is subject to each employee’s continued service as an employee of, or other service provider to, Intellia through the applicable vesting dates.
All of the above-described awards were granted outside of Intellia’s stockholder-approved equity incentive plans pursuant to Intellia’s 2024 Inducement Plan, as amended, which was initially adopted by the board of directors in June 2024. These awards were approved by Intellia’s compensation committee as a material inducement to entering into employment with Intellia in accordance with Nasdaq Listing Rule 5635(c)(4).
About Intellia Therapeutics
Intellia Therapeutics, Inc. (Nasdaq: NTLA) is a leading clinical-stage biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies. The company’s mission is to transform the lives of people with severe diseases by developing and commercializing potentially curative treatments. With deep scientific, technical and clinical development experience, Intellia aims to reset the standard for medicine by durably treating the root causes of disease. Learn more at intelliatx.com and follow us @intelliatx.
Investor Contact: Jason Fredette Vice President, Investor Relations and Corporate Communications Intellia Therapeutics, Inc. jason.fredette@intelliatx.com
What inducement grants did Intellia Therapeutics (NTLA) announce on June 5, 2026?
Intellia Therapeutics announced time-based RSU inducement grants totaling 47,150 common shares to six new employees. According to Intellia, these awards were granted on June 1, 2026 under its 2024 Inducement Plan as a material inducement to employment.
How many RSU shares were granted under Intellia Therapeutics’ 2024 Inducement Plan for NTLA?
Intellia granted an aggregate of 47,150 RSU shares of its common stock to six new employees. According to Intellia, these equity awards were made outside stockholder-approved plans, pursuant to the 2024 Inducement Plan, as amended, adopted in June 2024.
What is the vesting schedule for the new Intellia Therapeutics (NTLA) RSU inducement grants?
The RSU inducement grants vest in three equal annual installments over three years. According to Intellia, one-third of the RSUs vest each year, subject to each recipient’s continued employment or service through the applicable vesting dates.
Were Intellia Therapeutics’ June 2026 NTLA inducement grants made under stockholder-approved plans?
The June 2026 inducement grants were made outside Intellia’s stockholder-approved equity incentive plans. According to Intellia, they were issued under the 2024 Inducement Plan, as amended, which its board initially adopted in June 2024.
Why did Intellia Therapeutics grant RSU inducement awards under Nasdaq Listing Rule 5635(c)(4) for NTLA?
Intellia granted the RSU awards as a material inducement for six individuals to enter employment. According to Intellia, the compensation committee approved these grants in accordance with Nasdaq Listing Rule 5635(c)(4) governing equity awards to new employees.
How do the new Intellia Therapeutics (NTLA) inducement RSUs depend on employee service?
Vesting of the inducement RSUs depends on each recipient’s continued service with Intellia. According to Intellia, employees must remain employed or as service providers through each vesting date for their portion of RSUs to vest.
